Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis
Authors' conclusion
We identified three antibody biomarkers that are associated with failure to achieve remission/LDA after first-line RA therapy.
Study context
- Population
- Early rheumatoid arthritis (RA) patients from the Care in early RA (CareRA) trial, baseline sera, first-line therapy20 + 20 screening
- Comparison
- Anti-UH-RA.305/318/329 antibody positive vs negative
- Outcome
- Failure to reach remission or low disease activity (LDA) (DAS28CRP/ESR, CDAI/SDAI) after first-line therapy
Methodological detailsphage display library screening, multivariate analyses, secondary use of CareRA trial samples
- Phage display library screening
- Multivariate analyses
- Secondary use of CareRA trial samples
Performance
As reported in the abstract
Anti-UH-RA.305/318/329 antibody reactivity · week 8
P = 0.0031
Further findings
| Outcome | OR | P value |
|---|---|---|
| Failure to reach DAS28CRP sustained LDA, all patientsMultivariate analyses | 3.7 | P = 0.009 |
| Failure to reach DAS28ESR sustained LDA, all patientsMultivariate analyses | 2.76 | P = 0.042 |
Antibody targets in RA synovial tissue and SW982 cells
- Anti-UH-RA.305/329 antibodies were shown to target fibroblast-like synoviocyte (FLS) in RA synovial tissue and SW982 cells
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis. RMD Open. Published 17 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →